MegaPro Biomedical Co., Ltd

MegaPro Biomedical Co., Ltd is a biotechnology company focused on the development of nano drugs. Its pipeline includes MPB-1523, an IOP injection in Phase II clinical trials for hepatocellular carcinoma; MPB-1514, an iron injection in Phase II clinical trials for iron deficiency anemia; and MPB-1734, an anti-cancer drug in preclinical trials for malignant tumors. The company was founded in 2014 and is based in Zhubei, Taiwan.